中国麻风皮肤病杂志 ›› 2022, Vol. 38 ›› Issue (4): 260-264.doi: 10.12144/zgmfskin202204260

• 综述 • 上一篇    下一篇

酪氨酸激酶抑制剂治疗皮肤病新进展

宋洪彬,刘跃华   

  1. 北京协和医院皮肤科 中国医学科学院北京协和医学院，北京，100730
  • 出版日期:2022-04-15 发布日期:2022-02-10
  • 通讯作者: 刘跃华，E-mail: yuehualiu63@163.com

Progress in the treatment of skin diseases with tyrosine kinase inhibitors

SONG Hongbin, LIU Yuehua   

  1. Department of Dermatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China
  • Online:2022-04-15 Published:2022-02-10
  • Contact: LIU Yuehua, E-mail: yuehualiu63@163.com

PDF (PC)

231

摘要： 酪氨酸激酶（TKs）及其受体在肿瘤细胞生长、黏附、存活、分化、凋亡、血管生成和转移等过程中发挥重要作用，此外还参与免疫调节，因而迅速成为抗肿瘤的重要靶点之一。近年来TK抑制剂（TKIs）已用于治疗隆突性皮肤纤维肉瘤、黑素瘤、肥大细胞增生症、嗜酸性粒细胞

关键词: 酪氨酸激酶抑制剂, 隆突性皮肤纤维肉瘤, 黑素瘤, 肥大细胞增生症, 嗜酸性粒细胞增多综合征

Abstract: Tyrosine kinases (TKs) and their receptors play an important role in the growth, adhesion, survival, differentiation, apoptosis, angiogenesis and metastasis of tumor cells. In addition, they are involved in immune regulation, which make them become the important targets of anti-tumor. TK inhibitors (TKIs) have been applied to treatment of dermatofibrosarcoma protuberans, melanoma, mastocytosis, hypereosinophilic syndrome and other skin diseases. The update of the first and second generation TKIs in the treatment of skin diseases is reviewed in this paper.

Key words: tyrosine kinase inhibitor, dermatofibrosarcoma protuberans, melanoma, mastocytosis, hypereosinophilic syndrome